

Product Licence Number	Company Name	Product Name	Active Ingredients	Indications	Date of Authorisation
0201/0178	Schering-Plough Limited	Uni-Dur Sustained Release Tablets 600 mg	Theophylline Anhydrous EP 600 mg	See PL/0201/0177.	13th January 1994
0221/0128	Amersham International PLC	Myoview™	Tetrofosmin HSE 0.23 mg	As an adjunct in the diagnosis and localization of myocardial ischaemia and/or infarction. POM	5th January 1994
0289/0285	Approved Prescription Services Limited	Lactulose Solution BP	Lactulose HSE 3.5 gm Lactose BP 0.2 gm Galactose HSE 0.47 gm	Constipation, Hepatic encephalopathy (portal systemic encephalopathy): Hepatic coma. PM	16th March 1994
0337/0225	Napp Laboratories Limited	MST Continus Suspension 60mg	Morphine (equivalent to Morphine Sulphate) BP 60.0 mg	For the prolonged relief of severe pain. POM	14th January 1994
0337/0226	Napp Laboratories Limited	MST Continus Suspension 100 mg	Morphine (equivalent to Morphine Sulphate) BP 100.0 mg	See PL/0337/0225	14th January 1994
0337/0227	Napp Laboratories Limited	MST Continus Suspension 200 mg	Morphine (equivalent to Morphine Sulphate) BP 200.0 mg	See PL/0337/0225	14th January 1994
0440/0069	Galen Limited	Plegivex Cardioplegia Solution (St. Thomas No. 1 Formulation)	Sodium Chloride BP 0.86% w/v Potassium Chloride BP 0.149% w/v Calcium Chloride BP 0.033% w/v Magnesium Chloride BP 0.325% w/v Procaine Hydrochloride BP 0.027% w/v	Used to effect cold cardioplegia during cardiothoracic surgery involving valve replacement. POM	11th January 1994
0530/0400	Norton Healthcare Limited	Atenolol Tablets BP 25 mg	Atenolol BP 25.0 mg	Management of hypertension, angina pectoris, cardiac dysrhythmias. Myocardial infarction (early intervention in the acute phase). POM	28th March 1994
0637/0022	Nycomed Imaging AS	Abdoscan Granules for Oral Suspension	Iron Ferrite with carrier particles HSE 100.0 mg (equivalent Iron) (23.4 mg)	For diagnostic magnetic resonance imaging (MRI) in adults with suspected or known abdominal pathology. For labelling of the bowel during MRI-Assessment of Masses in abdomen, pelvis and for retroperitoneum, eg in pancreatic disease, enlarged lymph nodes and tumours. POM	26th January 1994
1511/0058	Secretary of State for Health	Anthrax Vaccine	Anthrax Antigens HSE	For prophylaxis in circumstances where exposure to bacillus anthracis may be expected or anticipated. POM	6th January 1994
3132/0104	Novo Nordisk Pharmaceuticals Limited	Actrapid Pen	Human Insulin (PYR) BP 100 iu	The treatment of insulin-requiring diabetics. PM	13th January 1994
3243/0273	Munro Wholesale Medical Supplies Limited	Timormin 25 mg	Atenolol 25.0 mg	(a) Control of Hypertension. (b) Management of Angina Pectoris. (c) Control of cardiac dysrhythmias. (d) Treatment of myocardial infarction. Early intervention in the acute phase. POM	7th April 1994
3433/0169	Farmitalia Carlo Erba Limited	Dostinex Tablets 0.5 mg	Cabergoline HSE 0.5 mg	For the inhibition of physiological lactation soon after delivery and for suppression of already established lactation: (1) After parturition, when the mother elects not to breast feed the infant or when breast feeding is contraindicated due to medical reasons related to the mother or the new born. (2) After still birth or abortion. POM	12th January 1994
3787/0283	Swingward (t/a Spectrum Marketing)	Tagamet 200 mg Tablets	Cimetidine 200.0 mg	(1) Benign gastric and duodenal ulceration, including that associated with non-steroidal anti-inflammatory drugs: symptomatic relief and healing. (2) Benign gastric and duodenal ulceration: maintenance of healing. (3) Oesophageal reflux disease: symptomatic relief, and healing of oesophagitis. (4) Zollinger-Elison syndrome: symptomatic relief, and healing of peptic ulcers. (5) Recurrent ulceration: symptomatic relief and healing of ulcers. (6) Stomal ulceration: symptomatic relief and healing of ulcers. (7) Other conditions where reduction of gastric acid has been shown to be beneficial: (a) Relief of persistent dyspeptic symptoms with or without ulceration, particularly meal related upper abdominal pain, including such symptoms associated with non-steroidal anti-inflammatory drugs. (b) Prophylaxis of haemorrhage from "stress" ulceration in critically ill patients. (c) Acid aspiration syndrome: Prophylaxis in general surgical and obstetric patients at risk. (d) Short bowel syndrome: to reduce malabsorption and fluid loss.	25th March 1994